Key Documents

View All Documentation

SML0142

Valsartan

Name: Valsartan
Brand: SIGMA

≥98% (HPLC), Angiotensin II type 1 (AT1) receptor antagonist, powder

Synonym(s):

N-(1-Oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₄H₂₉N₅O₃

CAS Number:

137862-53-4

Molecular Weight:

435.52

UNSPSC Code:

12352200

PubChem Substance ID:

329825190

NACRES:

NA.77

MDL number:

MFCD00865840

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Storage condition:

desiccated

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Valsartan, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -55 to -70°, c = 1 in methanol

storage condition

desiccated

color

white to tan

solubility

DMSO: ≥20 mg/mL

originator

Novartis

storage temp.

2-8°C

SMILES string

CCCCC(=O)N(Cc1ccc(cc1)-c2ccccc2-c3nnn[nH]3)[C@@H](C(C)C)C(O)=O

InChI

1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1

InChI key

ACWBQPMHZXGDFX-QFIPXVFZSA-N

Gene Information

human ... AGTR1(185)

Description

Application

Mice were treated with valsartan to study the role of Ang II-dependent pathway in aldosterone-related effects.

Biochem/physiol Actions

Valsartan is an Angiotensin II type 1 (AT1) receptor antagonist and anti-hypertensive. Valsartan renders protection against heart attack and stroke resulting from abrupt increase in blood pressure. Valsartan reduces myocardial-infarction-related complications in heart attack survivors.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Valsartan

pictograms

GHS08,GHS07

signalword

Warning

hcodes

H336,H361d

Hazard Classifications

Repr. 2 - STOT SE 3

target_organs

Central nervous system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

pcodes

P202 - P261 - P271 - P280 - P304 + P340 + P312 - P308 + P313

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

123M4716V

091M4728V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Discover Bioactive Small Molecules for ADME/Tox

Angiotensin II receptor antagonists in the treatment of hypertension.

N M Kaplan

American family physician, 60(4), 1185-1190 (1999-10-03)

The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI) includes recommendations for the assessment of overall cardiovascular risk and the need for active antihypertensive drug therapy. Once the decision to

Valsartan in the treatment of heart attack survivors.

Bodh I Jugdutt

Vascular health and risk management, 2(2), 125-138 (2007-02-27)

Survivors of myocardial infarction (MI) are at high risk of disability and death. This is due to infarct-related complications such as heart failure, cardiac remodeling with progressive ventricular dilation, dysfunction, and hypertrophy, and arrhythmias including ventricular and atrial fibrillation. Angiotensin

Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway.

Frédéric Michel et al.

Circulation, 109(16), 1933-1937 (2004-04-14)

We analyzed the role of aldosterone in ischemia-induced neovascularization and the involvement of angiotensin II (Ang II) signaling in this effect. Ischemia was induced by right femoral artery ligature in mice treated or not with aldosterone (4.5 microg/day), aldosterone plus

View All Related Papers

Global Trade Item Number

SKU	GTIN
SML0142-10MG	04061837076954
SML0142-50MG	04061837076961